Account wins from the 02/17/06 News Brief

Share this article:
PDI announced a three-year agreement with Ascend Therapeutics to promote their estrogen replacement therapy product, EstroGel, to the obstetrician/gynecologist market. PDI will initially provide a specialty sales team of 50 field representatives, with the expectation the field force will grow over time. The program is due to run through Jan. 31, 2008, with an automatic extension through Jan. 31, 2009, if certain conditions are met.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.